Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib after or with low-dose ruxolitinib in myelofibrosis
NL-OMON48854Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of itacitinib and ruxolitinib in myelofibrosis (MF) (2 cohorts), sponsored by Incyte. Primary endpoint: Change and percentage change in spleen volume reduction at Week 24. Started Jun 2019; status: active, not recruiting.
02
Drugs
itacitinibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON48854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48854.